Last reviewed · How we verify
Streptococcus pneumoniae inoculation
At a glance
| Generic name | Streptococcus pneumoniae inoculation |
|---|---|
| Also known as | S. Pneumoniae |
| Sponsor | Genocea Biosciences, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire (PHASE4)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (PHASE1)
- A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
- Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases (PHASE4)
- The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Streptococcus pneumoniae inoculation CI brief — competitive landscape report
- Streptococcus pneumoniae inoculation updates RSS · CI watch RSS
- Genocea Biosciences, Inc. portfolio CI